Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
for post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery, marking full enrollment in this 16-week, double-blind, placebo-controlled study. This milestone moves Amylyx closer to potentially filing for approval of a first-in-class GLP-1 receptor antagonist in a condition with no FDA-approved therapies, informed by earlier trials showing consistent reductions in severe hypoglycemic events. We'll now examine how completing enrollment in this pivotal LUCIDITY trial could reshape Amylyx's investment narrative and future outlook. Find 61 companies with promising cash flow potential yet trading below their fair value Amylyx Pharmaceuticals Investment Narrative Recap The core belief behind owning Amylyx today is that avexitide can become the first approved therapy for post bariatric hypoglycemia and anchor a broader GLP 1 antagonist and neurodegeneration portfolio. Completing enrollment and dosing in the LUCIDITY Phase 3 trial materially clarifies the path to the ke
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch [Yahoo! Finance]Yahoo! Finance
- Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire
- Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $34.00 price target on the stock.MarketBeat
AMLX
Earnings
- 3/3/26 - In-Line
AMLX
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/24/26 - Form 8-K
- 3/9/26 - Form 4
- AMLX's page on the SEC website